entertainment -WSS

entertainment

author：comprehensive 2025-09-30 17:04:15 - browse：6

Sarepta - Cambridge -AP — A logo sign outside of the headquarters of Sarepta Therapeutics in Cambridge, Mass. Kristoffer Tripplaar/Sipa via AP

Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to intervene earlier this year, according to three people with direct knowledge of the agency deliberations.

Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta’s gene therapy should be rejected, the individuals said, speaking on condition of anonymity. Peter Marks, a top FDA official and vocal advocate for faster gene therapy approvals, stepped in and directed staff to schedule a public hearing on the therapy on May 12.

Sarepta announced the scheduling of the public hearing last month, but the internal deliberations that led to it have not been previously reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Leqembi, other new Alzheimer’s drugs require better biomarkers

WSS

How climate

The EU Joint Clinical Assessment needs to live up to its promise

What to know about OceanGate, the company behind the missing Titanic submersible

STAT Readout Newsletter: Today's biggest biotech updates

California’s proposed $25 per hour health care minimum wage

Retired US general questions alleged Putin, Prigozhin meeting

explore

entertainment

Wikipedia

Psychedelics group wrestles with new pharma identity

Hospital price transparency does save money, advocate argues

Tori Bowie and the unacceptable rates of Black maternal death

Solve the antibiotic resistance crisis with preventive drugs

Hepatitis C has a cure — but many Americans still lack access to it

Oak trusses raised to roof of fire

Apple is now the first public company to be valued at $3 trillion

Hospital price transparency does save money, advocate argues

Cancer drug shortages should be causing more outrage

Bulgari apologizes to China for listing Taiwan as a country after online backlash

knowledge

Elizabeth Holmes on track for early release from her 11

New research casts further doubt on a common procedure used with IVF

CEOs share strategies for surviving biotech slump

STAT Readout Newsletter: Today's biggest biotech updates

Why ADHD is under

HHS leader on health, climate change and biopharma emissions

entertainment

entertainment

hotspot

explore